Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia - Results from the ECLIPSE study

被引:25
作者
Faergeman, Ole [1 ]
Hill, Laurie [2 ]
Windler, Eberhard [3 ]
Wiklund, Olov [4 ]
Asmar, Roland [5 ]
Duffield, Emma [6 ]
Sosef, Froukje [7 ]
机构
[1] Aarhus Sygehus Univ Hosp, DK-8000 Aarhus C, Denmark
[2] Brampton Cardiopulm Serv, Brampton, ON, Canada
[3] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[4] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[5] Inst Cardiovasc, Paris, France
[6] AstraZeneca, Macclesfield, Cheshire, England
[7] AstraZeneca, Molndal, Sweden
关键词
rosuvastatin; atorvastatin; low-density lipoprotein cholesterol; hypercholesterolemia;
D O I
10.1159/000127442
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia. Methods: In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). Results: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of < 100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of < 2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of < 70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin also achieved significantly greater improvements in components of the atherogenic lipid profile versus atorvastatin. Both treatments were well tolerated. Conclusion: Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:219 / 228
页数:10
相关论文
共 29 条
[1]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[2]  
Balbisi EA, 2006, MED SCI MONITOR, V12, pRA34
[3]  
Bourgault C, 2005, CAN J CARDIOL, V21, P1187
[4]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]   Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].
Cohen, JC ;
Boerwinkle, E ;
Mosley, TH ;
Hobbs, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272
[7]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[8]   Statin safety: An assessment using an administrative claims database [J].
Cziraky, MJ ;
Willey, VJ ;
McKenney, JM ;
Kamat, SA ;
Fisher, MD ;
Guyton, JR ;
Jacobson, TA ;
Davidson, MH .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :61C-68C
[9]   European guidelines on cardiovascular disease prevention in clinical practice -: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2003, 10 (04) :S1-S10
[10]   Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease [J].
Faergeman, O .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (05) :434-436